Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091567 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
A Phase 3 study of Small-cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
- 20
- Study locations
NCT05091567: Active Phase 3 study of Small-cell Lung Cancer, sponsored by Hoffmann-La Roche.
NCT05091567 is a Phase 3 study of Small-cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 660 participants, above the 224-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091567, a Phase 3 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
Primary Outcome
PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relat
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Etoposide
- DRUG Lurbinectedin
Study Locations (20)
Other
- Institut Jules Bordet - Anderlecht
- Jessa Zkh (Campus Virga Jesse) - Hasselt
- UZ Leuven Gasthuisberg - Leuven
- AZ St Maarten Campus Leopoldstr - Mechelen
- CHU UCL Mont-Godinne - Mont-godinne
- Vitaz - Sint-Niklaas
Tennessee
- Greco-Hainesworth Centers for Research - Chattanooga
- West Clinic - Germantown
- Sarah Cannon Research Institute / Tennessee Oncology - Nashville
Georgia
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Marietta
Illinois
- Illinois Cancer Care - Peoria
Maine
- New England Cancer Specialists - Scarborough
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Missouri
- Mercy Research - St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2026-08-13 |
| Phase | Phase 3 |
What the registry record for NCT05091567 still lists
NCT05091567 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, above the 224-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (195% higher).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT05091567 names 20 study sites across 13 states, led by Other, Tennessee, Georgia.
Frequently Asked Questions
What is clinical trial NCT05091567 about?
NCT05091567 is a clinical study titled "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer". Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with...
What is the current status of trial NCT05091567?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2021-11-18. Estimated completion is 2026-08-13.
What conditions does trial NCT05091567 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT05091567?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05091567?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091567 being conducted?
This trial has 20 study locations across Georgia, Illinois, Maine, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05091567's enrollment target sits among peer trials
660 7th of 79 higher than 73 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI